Cargando empresa
Just reported
Q3 2026 results
From Clover Health Investments's results release of 4 de noviembre de 2026; its quarterly report has since been filed.
Revenue
Actual
759,3M US$
+53 % y/y
+2,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
0,01 US$
-80 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
6,4M US$
-77 % q/q
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue2,97B US$ – 3B US$+55 % y/y Raised +0,8 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Clover Health Investments is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Healthcare Plans
Graded A or B and worth $2B or more: A first, then the largest.
CVSCVS Health Corp114,5B US$A
CIThe Cigna Group79,4B US$A
OSCROscar Health, Inc.10B US$A
HUMHumana Inc.53,6B US$B
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A- CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Estados financieros completos →
Construido a partir de los propios informes de Clover Health Investments, Corp. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
